Physician profile
William Hsueh
NPI 1972948164
$3,419.68
in general payments reported to CMS, 2019-2025
25 companies · $575 in 2025
The $575 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2021: $392 · 2022: $929 · 2023: $506 · 2024: $899 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,979.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $780.96 | 2021-2025 | |
| Janssen Biotech, INC. | $570.23 | 2019-2025 | Tremfya, Stelara, Na |
| Boston Scientific Corporation | $508.61 | 2021-2025 | Acquire, Autotome Rx 49, Spyglass |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $329.99 | 2021-2025 | Xifaxan |
| Celgene Corporation | $231.99 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $164.73 | 2019-2024 | Entyvio |
| Madrigal Pharmaceuticals | $105.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Kiniksa Pharmaceuticals, LTD. | $96.94 | 2022 | |
| Genzyme Corporation | $90.47 | 2023-2024 | |
| Ardelyx, INC. | $74.29 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $59.13 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $58.32 | 2021-2024 | |
| Novo Nordisk INC | $52.50 | 2025 | Wegovy |
| Qol Medical, LLC | $48.49 | 2024 | Sucraid |
| Merck Sharp & Dohme LLC | $40.36 | 2022-2023 | Recarbrio, Zinplava, Zerbaxa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $29.87 | 2023 | Evis Exera Lll Colonovideoscope |
| Janssen Pharmaceuticals, INC | $27.91 | 2024 | Xarelto |
| Lilly USA, LLC | $23.72 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $22.12 | 2023 | Dupixent |
| Pentax of America, INC. | $21.83 | 2023 | N/A |
| Aimmune Therapeutics, INC. | $21.66 | 2024 | |
| Insulet Corporation | $15.91 | 2021 | |
| Braintree Laboratories, INC. | $15.18 | 2023 | Sutab |
| Phathom Pharmaceuticals, INC. | $14.96 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $14.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hsueh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.